Narcolepsy

Human brain
#Acquisition #CNS #Excessive Daytime Sleepiness (EDS) #Narcolepsy #Neuraxpharm #Neuroscience #TG Therapeutics

Narcolepsy acquisitions to boost Neuraxpharm’s CNS reach

Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More

#Business & Investment #News

#Centessa Pharmaceuticals #Clinical trials #Narcolepsy #Neuroscience #Sleep disorders

Centessa initiates Phase II trial in patients with sleep/wake disorders 

Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.  ORX750 was designed using Nxera Pharma technology to directly… Read More

#News